Abstract
Background: Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Methods: Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were reviewed. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of >4 months defined success); adverse events and quotes from the medical record on decision-making were also recorded. Results: Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). The median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 4.3, 5.6 months). An exploratory comparison, based on no cancer progression with irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 5.1, 9.3 months) versus 4.3 months (95% CI: 2.3, 4.8 months); p = 0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrate several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI. Conclusion: Nal-IRI might be considered in pancreas cancer patients who had received irinotecan, particularly in the absence of disease progression with the latter.
Original language | English (US) |
---|---|
Pages (from-to) | 379-383 |
Number of pages | 5 |
Journal | Pancreatology |
Volume | 21 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- Guidelines
- Irinotecan
- Liposomal
- Pancreas cancer
- Survival
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Gastroenterology